I provide independent and original analysis, pricing metrics and recommendations for the stem, cell, gene and regenerative therapy equities.

bluebird bio (BLUE), European Medicines Agency (EMA) grants access to its Priority Medicines (PRIME)

September 27, 2016

For LentiGlobin drug product in the treatment of patients with transfusion-dependent beta-thalassemia (TDT).  

Adverum Biotech (ADVM) pre-clinical data on 2 gene therapy candidates for the treatment of Wet AMD

September 16, 2016

Data shows it might be possible to achieve the same degree of CNV inhibition using an intra-vitreally delivered novel vector with an optimized AAV capsid, expression cassette, and anti-VEGF cDNA as the standard-of-care  

Histogenics Corporation (HSGX) proposes $30 M Private Placement

September 16, 2016

HSGX will sell 2,653,553 shares at a price of $2.25 per share and 24,158.8688 shares of newly created Series A Convertible Preferred Stock, which shares of preferred stock are convertible into approximately 10,679,781 shares of common stock.  Purchasers will receive warrants to purchase up to approximately 13,333,334 shares of common stock at an exercise price of $2.25 per share.   

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.